The past FY25/1Q26 results confirmed sequential improvement in the fundamentals of China's healthcare sector, propelled by innovative drugs and CDMOs, Citi said in a report. Domestic medical technology, healthcare services and pharmacy segments have bottomed out. Innovation is beginning to generate returns. Sales of innovative drugs are accelerating, while CXO order volumes have notched a record high.Citi updated its Hong Kong Buy list, which includes HENGRUI PHARMA (01276.HK) -0.400 (-0.578%) Short selling $92.68M; Ratio 19.987% , CSPC PHARMA (01093.HK) -0.060 (-0.740%) Short selling $90.59M; Ratio 14.677% , ASCLETIS-B (01672.HK) +0.250 (+1.479%) Short selling $1.71M; Ratio 6.193% , INNOVENT BIO (01801.HK) -1.650 (-1.860%) Short selling $106.70M; Ratio 17.740% , WUXI APPTEC (02359.HK) +0.503 (+0.368%) Short selling $122.45M; Ratio 20.510% , WUXI BIO (02269.HK) +0.160 (+0.475%) Short selling $133.28M; Ratio 20.218% , ALI HEALTH (00241.HK) -0.030 (-0.667%) Short selling $126.76M; Ratio 34.055% , MEDBOT-B (02252.HK) -0.880 (-3.177%) Short selling $3.65M; Ratio 2.570% , MINDRAY BIO-MEDICAL (300760.SZ) -0.450 (-0.270%) , AIER EYE (300015.SZ) +0.330 (+3.125%) and YIFENG PHARMACY (603939.SH) +0.070 (+0.300%) . Its Top Sells include CR MEDICAL (01515.HK) -0.040 (-1.429%) Short selling $2.21M; Ratio 26.011% and BLOOMAGE BIOTECH (688363.SH) +0.460 (+1.121%) . (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.) (A Shares quote is delayed for at least 15 mins.)Related News JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO (01801.HK), WUXI APPTEC (02359.HK), WUXI XDC (02268.HK), SKB BIO (06990.HK)
AASTOCKS Financial News